WASHINGTON (AP) - A panel of arthritis experts has recommended that the federal government allow continued testing of an experimental class of pain drugs for arthritis, despite links to bone decay and joint failure
The Food and Drug Administration's 21-member panel of arthritis experts voted unanimously that research on the nerve-blocking drugs should continue, with certain safety precautions to protect patients. Reports of
joint failure led the agency to halt studies of the drugs in 2010.
Pfizer, Johnson & Johnson and Regeneron Pharmaceuticals have asked the FDA to lift the moratorium on testing of their drugs.
"There's clearly a worrisome safety signal, but in spite of that I think there's an unmet need in certain patient populations," said panelist Dr. Sherine Gabriel, of the Mayo Medical School of Rochester of Minnesota.
- FDA Panel Supports Continued Testing of Pain Drugs
- New Treatments for Back Pain Suffers
- New Drug Suppliers to Ease Two Cancer Drug Shortages
- Florida Man Charged in $80M Drug Heist Pleads Not Guilty
- National Drug Take-Back Day
- Counterfeit Drugs Are Big Business
- Drug Sting
- Roc-A-Fella Pleads Guilty To Drugs
- Georgia to Require Drug Tests for Welfare Benefits
- FDA Review Favors First Drug for HIV Prevention